Výsledky vyhledávání - "Suragani RNVS"

Akademický článek

The activin receptor ligand trap ActRIIB:ALK4-Fc ameliorates cardiomyopathy induced by neuromuscular disease and diabetes.

Autor: Li J; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Fredericks M; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Tang M; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Cannell M; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Joshi S; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Kumar R; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Andre P; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., Suragani RNVS; Discovery Group, Acceleron Pharma Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Publikováno v: FEBS letters [FEBS Lett] 2022 Dec; Vol. 596 (24), pp. 3145-3158. Date of Electronic Publication: 2022 Aug 29.

Zobrazit plný text záznamu

Akademický článek

Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily.

Autor: Kumar R; Acceleron Pharma, Cambridge, MA, USA., Grinberg AV; Acceleron Pharma, Cambridge, MA, USA.; Dragonfly Therapeutics, Waltham, MA, USA., Li H; Acceleron Pharma, Cambridge, MA, USA., Kuo TH; Acceleron Pharma, Cambridge, MA, USA., Sako D; Acceleron Pharma, Cambridge, MA, USA., Krishnan L; Acceleron Pharma, Cambridge, MA, USA., Liharska K; Acceleron Pharma, Cambridge, MA, USA.; Dragonfly Therapeutics, Waltham, MA, USA., Li J; Acceleron Pharma, Cambridge, MA, USA., Grenha R; Acceleron Pharma, Cambridge, MA, USA., Maguire MC; Acceleron Pharma, Cambridge, MA, USA., Briscoe SD; Acceleron Pharma, Cambridge, MA, USA., Pearsall RS; Acceleron Pharma, Cambridge, MA, USA.; Cellarity, Cambridge, MA, USA., Herrin BR; Acceleron Pharma, Cambridge, MA, USA., Suragani RNVS; Acceleron Pharma, Cambridge, MA, USA. rsuragani@acceleronpharma.com., Castonguay R; Acceleron Pharma, Cambridge, MA, USA. rcastonguay@acceleronpharma.com.

Publikováno v: Scientific reports [Sci Rep] 2021 Sep 15; Vol. 11 (1), pp. 18341. Date of Electronic Publication: 2021 Sep 15.

Zobrazit plný text záznamu

Akademický článek

Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.

Autor: Martinez PA; Acceleron Pharma, Cambridge, MA, USA., Li R; Acceleron Pharma, Cambridge, MA, USA., Ramanathan HN; Acceleron Pharma, Cambridge, MA, USA., Bhasin M; BIDMC Beth Israel Deaconess Medical Center, Harvard Medical School, Cambridge, MA, USA., Pearsall RS; Acceleron Pharma, Cambridge, MA, USA., Kumar R; Acceleron Pharma, Cambridge, MA, USA., Suragani RNVS; Acceleron Pharma, Cambridge, MA, USA.

Publikováno v: Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Jun; Vol. 24 (11), pp. 6162-6177. Date of Electronic Publication: 2020 Apr 29.

Zobrazit plný text záznamu

Akademický článek

Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.

Autor: Pearsall RS; Acceleron Pharma, Cambridge, MA, USA. spearsall@xlrn.com., Davies MV; Acceleron Pharma, Cambridge, MA, USA., Cannell M; Acceleron Pharma, Cambridge, MA, USA., Li J; Acceleron Pharma, Cambridge, MA, USA., Widrick J; Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Mulivor AW; Acceleron Pharma, Cambridge, MA, USA.; The Hospital for Sick Children, Toronto, Ontario, Canada., Wallner S; Acceleron Pharma, Cambridge, MA, USA.; NovaRock Biotherapeutics, Princeton, NJ, USA., Troy ME; Acceleron Pharma, Cambridge, MA, USA., Spaits M; Acceleron Pharma, Cambridge, MA, USA., Liharska K; Acceleron Pharma, Cambridge, MA, USA.; Dragonfly Therapeutics, Waltham, MA, USA., Sako D; Acceleron Pharma, Cambridge, MA, USA., Castonguay R; Acceleron Pharma, Cambridge, MA, USA., Keates S; Acceleron Pharma, Cambridge, MA, USA., Grinberg AV; Acceleron Pharma, Cambridge, MA, USA.; Dragonfly Therapeutics, Waltham, MA, USA., Suragani RNVS; Acceleron Pharma, Cambridge, MA, USA., Kumar R; Acceleron Pharma, Cambridge, MA, USA.

Publikováno v: Scientific reports [Sci Rep] 2019 Aug 06; Vol. 9 (1), pp. 11392. Date of Electronic Publication: 2019 Aug 06.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.

Autor: Tanzi E; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Di Modica SM; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy., Bordini J; Vita-Salute San Raffaele University, Milan, Italy.; B-cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Olivari V; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Pagani A; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy., Furiosi V; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy., Silvestri L; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Campanella A; Vita-Salute San Raffaele University, Milan, Italy.; B-cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Nai A; Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Jul; Vol. 99 (7), pp. 1313-1325. Date of Electronic Publication: 2024 Apr 17.

Zobrazit plný text záznamu

Akademický článek

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.

Autor: Griñán‐Ferré, Christian^1,2 (AUTHOR), Jarné‐Ferrer, Júlia¹ (AUTHOR), Bellver‐Sanchís, Aina¹ (AUTHOR), Codony, Sandra³ (AUTHOR), Puigoriol‐Illamola, Dolors¹ (AUTHOR), Sanfeliu, Coral⁴ (AUTHOR), Oh, Yumin⁵ (AUTHOR), Lee, Seulki⁵ (AUTHOR), Vázquez, Santiago³ (AUTHOR), Pallàs, Mercè^1,2 (AUTHOR) pallas@ub.edu

Publikováno v: CNS Neuroscience & Therapeutics. Apr2024, Vol. 30 Issue 4, p1-20. 20p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.

Autor: Garbowski MW; UCL Cancer Institute Hematology Department, University College London, University College London Hospitals, London, UK., Ugidos M; BMS Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain., Risueño A; BMS Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain., Shetty JK; Celgene International Sàrl a Bristol-Myers Squibb Company, Boudry, Switzerland., Schwickart M; Formerly Bristol Myers Squibb, Summit, New Jersey, USA., Hermine O; Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Imagine Institute, INSERM Unité 1163, University of Paris, Paris, France., Porter JB; UCL Cancer Institute Hematology Department, University College London, University College London Hospitals, London, UK., Thakurta A; Formerly Bristol Myers Squibb, Summit, New Jersey, USA., Vodala S; Britstol Myers Squibb, Princeton, NJ, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. 182-192. Date of Electronic Publication: 2023 Oct 02.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání